Cannabis and Epilepsy: Scientific Evidence, Clinical Trials, and Market Impact of High-CBD Therapies
Cannabis-based medicine has entered the scientific and regulatory mainstream, with epilepsy at the forefront of its therapeutic promise. High-CBD, low-THC cannabis formulations are now recognized as legitimate, evidence-backed options for patients with treatment-resistant epilepsy. This report dives into the clinical validation of these therapies, major product milestones such as Epidiolex, and the global regulatory and […]